Jones S E, Lilien D L, O'Mara R E, Durie B G, Salmon S E
Med Pediatr Oncol. 1975;1(1):11-21. doi: 10.1002/mpo.2950010104.
A new radiopharmaceutical, indium-111 labeled bleomycin (IB), was evaluated as a tumor-imaging agent in 55 patients with lymphoma. Overall disease activity was correctly identified in 79% of 75 whole-body scan obtained 48 hours after intravenous administration of IB. Serial scans in 19 patients accurately reflected changes in their disease status. Lymphatic and soft tissues sites of involvement both above and below the diaphragm were most readily identified by scanning. Bone marrow and hepatic involvements were more difficult to detect because of normal tissue background in the considered organs. Five patients manifested diffuse pulmonary uptake of IB and only in one case was it explained. To determine the accuracy of scanning with IB, we evaluated 731 individual sites of potential tumor involvement with these results: true positives 90%, false negatives 10%, false positives 4%, and true negatives 96%. Thus, tumor scanning with indium-111 bleomycin is an important new technique for the initial staging and serial evaluation of patients with lymphoma.
一种新的放射性药物，铟 - 111标记的博来霉素（IB），在55例淋巴瘤患者中作为肿瘤显像剂进行了评估。在静脉注射IB后48小时获得的75次全身扫描中，79%正确识别了总体疾病活动情况。19例患者的系列扫描准确反映了其疾病状态的变化。通过扫描最容易识别横膈上下受累的淋巴组织和软组织部位。由于所考虑器官中的正常组织背景，骨髓和肝脏受累更难检测。5例患者表现出IB在肺部的弥漫性摄取，仅1例得到了解释。为了确定使用IB扫描的准确性，我们评估了731个潜在肿瘤受累的个体部位，结果如下：真阳性90%，假阴性10%，假阳性4%，真阴性96%。因此，用铟 - 111博来霉素进行肿瘤扫描是淋巴瘤患者初始分期和系列评估的一项重要新技术。
